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ABSTRACT
The efficacy of the addition of inhaled oxitropium
bromide in combination with inhaled corticosteroids in
the treatment of elderly asthmatic patients whose
asthma is not well controlled was evaluated. A random-
ized, open-label cross-over trial comparing 4-week
treatment periods with and without regular inhalation
of 200 m g of oxitropium bromide four times per day
was performed. Twenty-four patients (mean age ± SD:
62 ± 7 years) completed the study. The dose of beclo-
methasone dipropionate in this patient group was
1300 ± 800 m g/day. Forced expiratory volume in
1 second (FEV1) was significantly improved after treat-
ment with regular inhalation of oxitropium bromide
when compared with FEV1 after treatment without
oxitropium (1.73 ± 0.60 vs 1.63 ± 0.68). Both morn-
ing and evening peak expiratory flow rates were
significantly greater during the treatment period with
regular inhalation of oxitropium bromide. The score
for dyspnea/chest tightness was also significantly
improved during the oxitropium bromide period. There
was no statistically significant improvement in forced
vital capacity, scores for other symptoms or the fre-
quency of rescue inhalation of fenoterol. The results of
this study demonstrated that the addition of regular
inhalation of oxitropium bromide is beneficial in elderly
asthmatics whose asthma is not well controlled, even
when treated with high-dose inhaled steroids.
Key words: beclomethasone dipropionate, bronchial
asthma, dyspnea, inhaled corticosteroids, oxitropium
bromide, peak expiratory flow.
INTRODUCTION
Although inhaled corticosteroids are the established
treatment of choice in cases of chronic asthma, it is not
uncommon for even high doses of inhaled corticosteroids
to fail in achieving optimal control of asthma.1 The addi-
tion of other bronchodilators including sustained-release
theophylline and/or inhaled anticholinergic agents has
been recommended in the treatment of patients whose
asthma is not well controlled with inhaled corticoster-
oids.1 Inhaled anticholinergic agents administered by
single-dose inhalation have been shown to be effective in
terms of acute bronchodilation in patients with asthma.2–5
The long-term efficacy of drugs of this class, however,
remains to be adequately documented.
Inhaled anticholinergic agents have been regarded
as the drug of choice for patients with chronic obstruc-
tive pulmonary disease (COPD)6 due to the lower
incidence of systemic side-effects. It has been suggested
that they have a greater bronchodilating effect than
b 2-receptor agonists in elderly asthmatic patients.7 In
order to evaluate the efficacy of the addition of inhaled
oxitropium bromide in elderly asthmatic patients using
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inhaled corticosteroids and whose asthma was not
well controlled, we performed a randomized, open-
label cross-over trial.
METHODS
Subjects
Patients with chronic asthma aged 50 years or over who
had been suffering asthmatic symptoms and who had a
peak expiratory flow rate (PEF) of less than 85% of the
individual best value for 2 weeks were recruited. In total,
there were twenty-four patients (14 male and 10 female)
with ages ranging from 52 to 76 years (mean age ± SD:
62 ± 7 years).  All of the patients had received treatment
with a constant dose (400 m g/day or more) of beclo-
methasone dipropionate (BDP) for at least 2 weeks. The
diagnosis of asthma was based on the definition provided
by the the British Thoracic Society.1 For each patient it was
also confirmed that the improvement of PEF to inhaled
b 2-receptor agonists was more than 15%. Patients with
COPD or those taking other anti-asthma medications
apart from b 2-receptor agonists were excluded. Those
patients whose PEF recording was in doubt or whose
compliance with the inhalation technique was question-
able were also excluded. Informed consent was obtained
from all participants.
Study protocol
The efficacy of treatment with and without regular inhala-
tion of oxitropium bromide in addition to inhaled BDP
was compared using a randomized, open-labeled cross-
over trial. After a run-in period of at least 2 weeks’
duration, two continuous treatment periods of 4 weeks’
duration each were used. A total of 200 m g of oxitropium
bromide was administered four times per day by a
metered dose inhaler during the treatment period.
Education regarding inhalation technique, recording of
PEF and symptom scores was provided at least 2 weeks
prior to entry into the study and compliance was con-
firmed to be satisfactory by an attending physician during
the run-in period. The dose of BDP was kept at the same
level from 2 weeks before the entry to the end of the study.
Two puffs of fenoterol (400 m g) were prescribed on an
as-needed basis but no other medications were allowed.
Outcome measures
Outcome measurements included daily recording of
morning and evening PEF, symptom scores and frequency
of rescue inhalation of fenoterol during the last two weeks
of each 4-week treatment period as well as spirometry
performed at hospital visits before entry and at the end of
each treatment period. The baseline PEF and symptom
scores were recorded over the 2-week period just before
entry into the study.
The PEF was recorded twice daily before inhalation of
BDP with or without oxitropium bromide. A Personal Best
Peak Flow MeterTM (Health Scan, Cedar Grove, NJ, USA)
was used for ambulatory PEF measurement and a
maximum of three measurements was recorded. Three
subjective symptoms were recorded daily using a scoring
system ranging from 0 to 4 points (0 = never, 4 = severe):
dyspnea/chest tightness, coughing and sputum. The fre-
quency of the rescue inhalation using fenoterol was also
recorded.
The predicted values for the forced expiratory volume
in one second (FEV1) and forced vital capacity (FVC)
were those established by the Japan Society of Chest
Diseases.8 Peak expiratory flow was expressed as a per-
centage of the individual best value.
Statistical analysis
The paired t-test was performed for the analysis of FEV1,
FVC and PEF. The Wilcoxon signed-rank test was used for
the evaluation of symptom scores and the frequency of
rescue inhalation of fenoterol. A P value of less than
0.05 was considered statistically significant.
RESULTS
All 24 patients who participated completed the study. The
baseline FEV1 for patients was 1.60 ± 0.60 L or 60 ± 2%
of the predicted values. The dose of BDP in this patient
group was 1300 ± 800 m g/day (range: 400–2400 m g/
day). In 12 patients oxitropium bromide was administered
during the first treatment period, followed by the period
without oxitropium bromide. The other 12 patients received
oxitropium bromide in the second period.
FEV1 was significantly improved after treatment with
regular inhalation of oxitropium bromide when compared
with the measurements taken after treatment without
oxitropium (Table 1). Both morning and evening PEF
values were significantly better during the treatment period
with regular inhalation of oxitropium bromide than during
the period without oxitropium. The score for dyspnea/
chest tightness was also significantly improved during the
oxitropium bromide period. Scores for other symptoms
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were not significantly different between the two treatment
periods nor was the frequency of rescue fenoterol inhala-
tion. No order effects or carry-over effects were found
between the oxitropium-first and the oxitropium-second
regimens in the measurements of lung functions and
symptom scores.
No adverse side-effects were reported during the entire
study period.
DISCUSSION
The mean age of patients in this study was 62 years and
on average patients took 1300 m g of BDP. This indicated
that elderly patients whose asthma was not adequately
controlled even with high doses of BDP were investigated
in this study. The results of this study show the beneficial
effect of the addition of inhaled oxitropium bromide to
BDP on the study population. In this patient group
oxitropium bromide was shown to be effective in improv-
ing FEV1, PEF and the score for dyspnea/chest tightness.
Anticholinergic agents such as ipratropium bromide or
oxitropium bromide have been reported to have a signifi-
cant bronchodilating effect in asthmatic patients when
evaluated by single-dose acute bronchodilator response
tests.2–5 The addition of oxitropium bromide to BDP, as
shown in this study, was also associated with improve-
ments of PEF and FEV1, suggesting that the broncho-
dilating effect of this drug was maintained over the
4-week period and contributed to improved control of
chronic asthma.
The British Thoracic Society recommends a sequential
therapeutic trial of one or more of the following products as
a step 4 treatment where asthma cannot be adequately
controlled with 800–2000 m g/day of BDP: inhaled long-
acting b 2-agonists, sustained-release theophylline, inhaled
ipratropium or oxitropium, long-acting b 2-agonist tablets,
high dose inhaled bronchodilators, or cromoglycate or
nedocromil.1 Among these supplementary treatments,
inhaled long-acting b 2-receptor agonists9 and sustained-
release theophylline10 have been shown to have an additive
effect when combined with high doses of BDP in patients
with asthma. However, to date the efficacy of oxitropium
bromide in this regard has not been studied. This report is
the first to show the effect of adding oxitropium bromide to
BDP and confirms the validity of one of the recommen-
dations of the British Thoracic Society.
Although significant improvement was observed in the
present study, the magnitude of the improvement appears
to be rather small. Patients whose asthma is not ade-
quately treated even with high doses of BDP are not
uncommon and a comparison of the additive effects
and safety of various bronchodilating drugs including
sustained-release theophylline, long-acting b 2-receptor
agonists and anticholinergic agents is needed in patients
with asthma.
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Table 1. The additive effect of oxitropium bromide combined with beclomethasone dipropionate 
Baseline With OB Without OB P*
FEV1 (L) 1.61 ± 0.58 1.73 ± 0.60 1.63 ± 0.68 < 0.05
% predicted 60.5 ± 22.0 66.8 ± 22.2 62.0 ± 23.8 < 0.05
FVC (L) 2.61 ± 0.70 2.72 ± 0.63 2.61 ± 0.72 NS
% predicted 75.7 ± 15.5 81.6 ± 16.0 77.0 ± 16.3 NS
Morning PEF (L/min) 310 ± 70 320 ± 70 290 ± 67 < 0.001
% best 70 ± 9 74 ± 12 67 ± 11 < 0.001
Evening PEF (L/min) 330 ± 70 330 ± 80 310 ± 70 < 0.01
% best 73 ± 11 78 ± 13 72 ± 12 < 0.01
Weekly symptom scores
Dyspnea/Chest tightness (0–28) 11 ± 13 6 ± 13 10 ± 16 < 0.01
Cough (0–28) 17 ± 16 13 ± 18 15 ± 21 NS
Sputum (0–28) 22 ± 16 20 ± 19 21 ± 21 NS
Total symptom (0–84) 49 ± 34 38 ± 40 45 ± 50 NS
Frequency of rescue fenoterol inhalation
(per week) 6.0 ± 5.4 3.9 ± 5.4 4.4 ± 5.4 NS
OB, oxitropium bromide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; % best, percentage of the
individual best peak expiratory flow; NS, not significant; *, comparisons were made between two treatment periods. Values are expressed as mean ± SD.
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